Imatinib Powder

Product Details

Imatinib powder is used to treat all stages of chronic myeloid leukemia (CML), and it is also used to treat CD117-positive gastrointestinal stromal cell tumor (GIST). It is a small molecule protein tyrosine kinase inhibitor that can effectively inhibit the activity of BCR-ABL tyrosine kinase (TK) and the following TK receptors: Kit, stem cells encoded by the c-Kit proto-oncogene Factor (SCF) receptors, discoid domain receptors (DDR1 and DDR2), colony-stimulating factor receptors (CSF-1R), and platelet-derived growth factor receptors alpha and beta (PDGFR-alpha and PDGFR-beta).

Imatinib also inhibits the cellular behavior mediated by activation of these receptor kinases. In addition, imatinib can inhibit platelet-derived growth factor (PDGF) receptor, stem cell factor (SCF), tyrosine kinase of c-Kit receptor, thereby inhibiting cell behavior mediated by PDGF and stem cell factor. Imatinib-Intermediates,4-(4-Methylpiperazinylmethyl)benzoyl chloride dihydrochloride, is a white powder, an indispensable key body for the synthesis of imatinib.

Health Benefits

• For the treatment of the chronic phase, accelerated phase or blast phase of Philadelphia chromosome-positive chronic myeloid leukemia (Ph+CML).
• For the treatment of adult patients with unresectable and/or metastatic malignant gastrointestinal stromal tumors (GIST).
• Combined chemotherapy for the treatment of children with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL).
• For the treatment of adult patients with relapsed and refractory Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL).